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S184 Oral PresentationsTable 1. Summary of 21 SCT patients with BK viremia
High Viremia: Low Viremia:
>10,000
copies/ml
(n510)#10,000
copies/ml
(n511)p
valueUrine BK >1 billion copies/ml 8 (80%) 8/10 (80%) p>0.99**
Obstructive uropathy
requiring surgical interventions
5 (50%) 0 (0%) p50.01*Average maximum fold increase in
creatinine from pre-SCT6.4 2.1 p50.02***Renal replacement therapy 6 (60%) 1 (9%)# p50.02*
Biopsy proven polyoma
virus-associated nephropathy
3/3 samples none doneEnd stage renal disease 5 (50%) 0 (0%) p50.01*
Mortality attributed to BK virus 3 (30%) 0 (0%) p50.09*# Not attributed to polyoma virus-associated nephropathy.
*Fisher’s exact test.
**Unconditional exact test.
***Wilcoxon Two-Sample Test.82
HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN INFANTS
Leucht, S., Ashraf, K., Schechter, T., Doyle, J., Gassas, A. Hospital for Sick
Children, University of Toronto, Toronto, ON, Canada
Introduction: It is rare for an infant (less than 1 year old) to receive
HSCT and little is known about indications and outcomes in this
high risk population. Our objective herein was to review the indica-
tions and outcomes for all infants who received HSCT in a large
pediatric transplant centre.
Methods: A retrospective analysis of all children who receivedHSCT
was performed. Infants with an underlying immunological disorder
such as severe combined immune deficiency (SCID) were excluded.
Results: Between April 1992 and March 2010, 1363 (allogeneic 775,
autologous 588) children received HSCT in the Hospital for Sick
Children in Toronto. Fifty-one (3.7%) were infants. Seventeen infants
received allogeneic HSCT for an underlying metabolic disorder (os-
teopetrosis 7, Hurler syndrome 7, GM gangliosidosis 1, Niemann-
Pick type A 1 and Krabbes disease 1). The median age of diagnosis
was 78 days (antenatal-248 days). The median age at HSCT was 207
days (29-334 days). They all received myeloablative regimens. For
a median follow-up of 7.1 yrs (0.9-18.4 yrs) 13 patients are alive with
an overall survival in this group of 76%. Causes of death were TRM
in 3 and 1 patient (Niemann-Pick type A) died 4 ½ yrs post HSCT
from progressive disease despite full donor engraftment.
The remaining 34 infants, 10 received autologousHSCT (NBL 3,
AML 2, Brain tumor 3, Rhabdomyosarcoma 1, Retinoblastoma 1).
Twenty-four infants received allogeneic HSCT (13 related, 11 unre-
lated)- HLH 8, JMML 4, WAS 4, ALL 3, AML 2, SAA 1, CGD 1
and Amegakaryocytic Thrombocytopenia 1.Median age at diagnosis
was 103 days (1-200 days), median age at HSCT was 254 days (142-
365 days). All patients receivedmyeloablative regimens. For amedian
follow-up of 6.7 yrs (0.5-15.6 yrs) 25 infants are alive with an overall
survival in this group of 73%. Nine infants (27%) died, 6 due to
TRM and 3 because of disease relapse.
Eight out of ten infants who received autologous HSCT are long
term survivors.
Early post HSCT complications for all patients were mainly related
to feeding issues requiring long termNG/GT feeding. In terms of de-
velopmental and long term outcomes, the majority were delayed in
their developmental milestones at 12 months of age. However, most
of them caught up later on and attained good performance scales.
Conclusion: Our results for HSCT in infants are very encouraging
with good long term developmental mile stones and excellent
functional long term survival.83
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Rational:CD3-delta deficiency is a rare fatal form of SCID which is
potentially cured by hematopoetic stem cell transplantation
(HSCT). Being a rare disease optimal transplantation protocols for
this group of patients has not been established.
Methods: We retrospectively analyzed the data on 9 patients with
CD3-delta deficiency from 5 centers in Japan North America and
Europe that underwent HSCT, using different sources of donor
stem cells and different conditioning regimens.
Results:Mean age at HSCT was 5 months. 3 patients received stem
cells from a matched unrelated donor (MUD), with myeloablative
conditioning. They are alive and well. All of them experienced rapid
engraftment and full immune reconstitution. One of these patients
has recently delivered a healthy baby girl, 18y post BMT. 2 patients
received a matched cord transplant without conditioning. One of
them has had a partial but stable engraftment, while the other en-
grafted well but has only been followed for 12 months after
HSCT. Two other patients received a mismatched related donor
(MMRD). Both theses patients had failed to engraft and finally
died. Another 2 patients received stem cells from a matched related
donor (MRD), one with reduced conditioning regimen. This patient
lost his graft and recently underwent a second BMT. The other pa-
tient who received full conditioning is doing well and achieved full
immune reconstitution as well.
Conclusions: HSCT from MUD was successful. Myeloablative
conditioning may be necessary for engraftment of bone marrow de-
rived stem cells in these patients. It’s interesting to speculate that
cord stem cells may override that need.84
EXCELLENT SURVIVAL AFTER STEM CELL TRANSPLANTATION FOR NON-
SCID PRIMARY IMMUNODEFICIENCIES
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Allogeneic hematopoietic stem cell transplantation (HSCT) for
patients with Primary Immunodeficiencies (PIDs) has provided
a life saving therapy. There is less information available regarding
the utilization of stem cell transplantation for children with PIDs
other than SCID. We report the outcome following HSCT (1998-
2010) in 31 non-SCID patients: WAS (n 5 6), CGD (n 5 12),
LAD (n 5 3); and other T cell defects (n 5 10). The T cell defects
group included patients with NK cell defects (n5 2), X-linked lym-
phoproliferative disease (n5 2), NEMO (n5 1), HLA-class II defi-
ciency (n 5 1), Hyper IgM syndrome (n 5 1), DiGeorge Anomaly
(n 5 2) and Zap 70 deficiency (n 5 1). The patient median age at
transplant was 2.5 years (range, 0.3-16 years). Fourteen patients
received a matched related donor graft (MRD), thirteen patients re-
ceived a matched unrelated donor graft (MUD), two patients re-
ceived a mismatched unrelated donor graft and two patients
received a mismatched unrelated cord blood unit. Most patients (n
5 25) received a myeloblative conditioning consisting of busulfan,
cyclophosphamide, and fludarabine or cytarabine. Two patients re-
ceived total body radiation at 1400Gy. Only four patients received
a sub-myeloablative conditioning with cyclophosphamide and bu-
sulfan backbone with or without fludarabine. Two patients with
complete DiGeorge Syndrome were not conditioned. Graft vs host
disease (GvHD) prophylaxis usually combined cyclosporine and
metrotrexate or cyclosporine and prednisone.Most patients received
Campath to improve engraftment and to prevent GvHD. The me-
dian time for neutrophil recovery was 18 days (range, 12-37 days).
Twenty four patients achieved full donor chimerism (donor chime-
rism . 95%) and seven patients achieved mixed donor chimerism
(mean: 70%, range, 40-90%) but with correction of defective im-
mune function. There was no incidence of graft failure. Eight pa-
tients developed grade I aGvHD requiring only topical treatment.
Only one patient developed grade II-IV aGvHD. Chronic GvHD
